MedTrace Logo

Imaging Dopamine Release in Depression

NCT02033369 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-11-01

Study results available
· View outcomes & findings →

Summary

This study aims to determine whether ventral striatal dopamine release is a mechanism of reward motivation in major depression, whether dopamine release is low in depression, and whether DA release and reward motivation predict response to dopamine-targeted treatment with pramipexole.

Conditions

Interventions

DRUG

Pramipexole

Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.

Sponsors & Collaborators

  • Columbia University

    collaborator OTHER

  • Research Foundation for Mental Hygiene, Inc.

    collaborator OTHER

  • Mclean Hospital

    collaborator OTHER

  • Icahn School of Medicine at Mount Sinai

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Franklin Schneier, MD · NYSPI

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-12-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02033369 on ClinicalTrials.gov